Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904927807> ?p ?o ?g. }
- W2904927807 endingPage "519" @default.
- W2904927807 startingPage "519" @default.
- W2904927807 abstract "The EphA3 receptor has recently emerged as a functional tumour-specific therapeutic target in glioblastoma (GBM). EphA3 is significantly elevated in recurrent disease, is most highly expressed on glioma stem cells (GSCs), and has a functional role in maintaining self-renewal and tumourigenesis. An unlabelled EphA3-targeting therapeutic antibody is currently under clinical assessment in recurrent GBM patients. In this study, we assessed the efficacy of EphA3 antibody drug conjugate (ADC) and radioimmunotherapy (RIT) approaches using orthotopic animal xenograft models. Brain uptake studies, using positron emission tomography/computed tomography (PET/CT) imaging, show EphA3 antibodies are effectively delivered across the blood-tumour barrier and accumulate at the tumour site with no observed normal brain reactivity. A robust anti-tumour response, with no toxicity, was observed using EphA3, ADC, and RIT approaches, leading to a significant increase in overall survival. Our current research provides evidence that GBM patients may benefit from pay-loaded EphA3 antibody therapies." @default.
- W2904927807 created "2018-12-22" @default.
- W2904927807 creator A5007705014 @default.
- W2904927807 creator A5013079230 @default.
- W2904927807 creator A5014665196 @default.
- W2904927807 creator A5020288731 @default.
- W2904927807 creator A5026093475 @default.
- W2904927807 creator A5026411400 @default.
- W2904927807 creator A5028064086 @default.
- W2904927807 creator A5029356415 @default.
- W2904927807 creator A5034274387 @default.
- W2904927807 creator A5036264210 @default.
- W2904927807 creator A5038176647 @default.
- W2904927807 creator A5045157590 @default.
- W2904927807 creator A5053181257 @default.
- W2904927807 creator A5085683988 @default.
- W2904927807 creator A5088393367 @default.
- W2904927807 creator A5090491025 @default.
- W2904927807 date "2018-12-17" @default.
- W2904927807 modified "2023-10-17" @default.
- W2904927807 title "EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma" @default.
- W2904927807 cites W1584018958 @default.
- W2904927807 cites W1947523625 @default.
- W2904927807 cites W1986138661 @default.
- W2904927807 cites W1992187858 @default.
- W2904927807 cites W1997670728 @default.
- W2904927807 cites W2013698995 @default.
- W2904927807 cites W2019935679 @default.
- W2904927807 cites W2031984119 @default.
- W2904927807 cites W2036406012 @default.
- W2904927807 cites W2038385234 @default.
- W2904927807 cites W2059636734 @default.
- W2904927807 cites W2081758137 @default.
- W2904927807 cites W2089361666 @default.
- W2904927807 cites W2096287682 @default.
- W2904927807 cites W2114282952 @default.
- W2904927807 cites W2115100262 @default.
- W2904927807 cites W2116012295 @default.
- W2904927807 cites W2117692326 @default.
- W2904927807 cites W2124525074 @default.
- W2904927807 cites W2133105825 @default.
- W2904927807 cites W2140301591 @default.
- W2904927807 cites W2158681922 @default.
- W2904927807 cites W2161289668 @default.
- W2904927807 cites W2162488896 @default.
- W2904927807 cites W2163513494 @default.
- W2904927807 cites W2165871546 @default.
- W2904927807 cites W2166380408 @default.
- W2904927807 cites W2171368669 @default.
- W2904927807 cites W2463826053 @default.
- W2904927807 cites W2480222331 @default.
- W2904927807 cites W2526776358 @default.
- W2904927807 cites W2532758768 @default.
- W2904927807 cites W2766906603 @default.
- W2904927807 cites W2810882198 @default.
- W2904927807 cites W2903359836 @default.
- W2904927807 cites W2951880440 @default.
- W2904927807 doi "https://doi.org/10.3390/cancers10120519" @default.
- W2904927807 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6316644" @default.
- W2904927807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30562956" @default.
- W2904927807 hasPublicationYear "2018" @default.
- W2904927807 type Work @default.
- W2904927807 sameAs 2904927807 @default.
- W2904927807 citedByCount "23" @default.
- W2904927807 countsByYear W29049278072019 @default.
- W2904927807 countsByYear W29049278072020 @default.
- W2904927807 countsByYear W29049278072021 @default.
- W2904927807 countsByYear W29049278072022 @default.
- W2904927807 countsByYear W29049278072023 @default.
- W2904927807 crossrefType "journal-article" @default.
- W2904927807 hasAuthorship W2904927807A5007705014 @default.
- W2904927807 hasAuthorship W2904927807A5013079230 @default.
- W2904927807 hasAuthorship W2904927807A5014665196 @default.
- W2904927807 hasAuthorship W2904927807A5020288731 @default.
- W2904927807 hasAuthorship W2904927807A5026093475 @default.
- W2904927807 hasAuthorship W2904927807A5026411400 @default.
- W2904927807 hasAuthorship W2904927807A5028064086 @default.
- W2904927807 hasAuthorship W2904927807A5029356415 @default.
- W2904927807 hasAuthorship W2904927807A5034274387 @default.
- W2904927807 hasAuthorship W2904927807A5036264210 @default.
- W2904927807 hasAuthorship W2904927807A5038176647 @default.
- W2904927807 hasAuthorship W2904927807A5045157590 @default.
- W2904927807 hasAuthorship W2904927807A5053181257 @default.
- W2904927807 hasAuthorship W2904927807A5085683988 @default.
- W2904927807 hasAuthorship W2904927807A5088393367 @default.
- W2904927807 hasAuthorship W2904927807A5090491025 @default.
- W2904927807 hasBestOaLocation W29049278071 @default.
- W2904927807 hasConcept C142724271 @default.
- W2904927807 hasConcept C143998085 @default.
- W2904927807 hasConcept C159654299 @default.
- W2904927807 hasConcept C19831878 @default.
- W2904927807 hasConcept C203014093 @default.
- W2904927807 hasConcept C2775842073 @default.
- W2904927807 hasConcept C2776146153 @default.
- W2904927807 hasConcept C2776194525 @default.
- W2904927807 hasConcept C2778227246 @default.
- W2904927807 hasConcept C2780035454 @default.
- W2904927807 hasConcept C2989005 @default.